Outcomes of daclatasvir + sofosbuvir + riba in HEP C G3 patients who relapsed with SOF + RIBA combination therapy

Gill, Muzaffar Lateef

doi:10.1016/s0168-8278(17)31935-9

Cited by 2 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the overall successful SVR rates observed in the Pakistani population encourage the use of SOF in HCV-infected patients, there are still some exceptions leading to HCV relapse and non-responsiveness toward DAAs which should be considered before the use of DAAs in our population. A single-center study conducted on 100 patients, who relapsed after 24 weeks of treatment with SOF + RBV therapy, reported that addition of daclatsvir to the treatment regime (SOF + RBV therapy) resulted in 94% SVR in these patients after 24 weeks [ 78 ]. Wahid et al (2018) [ 77 ] reported a case report of a 77-year-old female patient diagnosed and treated with IFN-based therapy against HCV genotype 3a in January 2011.…”

Section: Preliminary Data Regarding the Success Rate Of Daas Againmentioning

confidence: 99%

Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan

Khaliq

Raza

2018

Medicina

View full text Add to dashboard Cite

In Pakistan, the burden of the hepatitis C virus (HCV) infection is the second highest in the world with the development of chronic hepatitis. Interferon-based combination therapy with ribavirin was the only available treatment until a few years back, with severe side-effects and high failure rates against different genotypes of HCV. Interferon-free all-oral direct-acting antiviral agents (DAAs) approved by the FDA have revolutionized the HCV therapeutic landscape due to their efficiency in targeting different genotypes in different categories of patients, including treatment naïve, treatment failure and relapsing patients, as well as patients with compensated and decompensated cirrhosis. The availability and use of these DAAs is limited in the developing world. Sofosbuvir (SOF), a uridine nucleotide analogue and inhibitor of HCV encoded NS5B polymerase, is now a widely available and in-use DAA in Pakistan; whereas daclatasvir was recently added in the list. According to the documented results, there is hope that this disease can be effectively cured in Pakistan, although a few concerns still remain. The aim of this article is to review the effectiveness of DAAs and the current status of this treatment against HCV genotype 3 infection in Pakistan; various factors associated with SVR; its limitations as an effective treatment regime; and future implications.

show abstract

Section: Preliminary Data Regarding the Success Rate Of Daas Againmentioning

confidence: 99%

Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan

Khaliq

Raza

2018

Medicina

View full text Add to dashboard Cite

show abstract

“…Appendix S2 reports the characteristics of each of the 49 included studies (34 full‐length papers and 15 abstracts). Three studies 33,42,55 were RCTs (one evaluating SOF/DCV versus SOF/LDV and two evaluating SOF/LDV for 8 weeks versus 12 weeks), 28 were non‐randomized controlled trials, 6–13,16,17,25–28,30,34,40,41,45,46,52–54,58,61,62 and 18 were observational studies 29,31,36,38,39,43,44,47–51,56–60,63 . Twenty‐four studies were conducted in Egypt, five in India, two in Pakistan, one each in Iraq, Italy, the United Kingdom, the United States of America, Brazil, and Bangladesh, and the remaining 12 were conducted in multiple sites.…”

Section: Resultsmentioning

confidence: 99%

“…We identified 7005 citations from PUBMED search, 690 from EMBASE search, 111 from CENTRAL search, and 15 records from conference abstracts. Through abstract and full‐text screening and review of other sources, 49 studies (34 full‐length papers 6–12,16,17,25–49 and 15 abstracts 13,50–63 ) were included in the final synthesis.…”

Section: Resultsmentioning

confidence: 99%

“…Across all studies, there were 30 Table 1 summarizes the key characteristics of 49 included studies. Overall, 36 study arms 6,8,11,13,16,25,[28][29][30][31][32][33][34][35][39][40][41][43][44][45][46][48][49][50][51][52][53][54][55][56][57][58][59][60]62,63 included 1882 adolescents (12-18 years), 12 7,9,12,13,17,26,27,36,37,47,54,61 included 436 older children (6-11 years), seven 7,10,…”

Section: Description Of the Overall Study Populationmentioning

confidence: 99%

“…Overall, they received SOF/LDV (142 children, 32.6%, three study arms, Table1), SOF + RBV (102, 23.4%, three study arms), SOF/VEL (73, 16.7%, one study arm), and GLE/PIB (56, 12.8%, one study arm). Across all DAA regimens, the majority received treatments for 12 weeks (258 children,59.2%, eight study arms), 92 (21.1%, four study arms) had 24-week regimens (89 with SOF + RBV, and 3 with SOF/LDV), and 30 were treated for 8 weeks, all with SOF/LDV. There was only one known HIV/HCV coinfected child who received 8weeks of GLE/ PIB 12.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta‐analysis

Indolfi,

Easterbrook,

Giometto

et al. 2024

Liver International

View full text Add to dashboard Cite

Background and AimsWe evaluated the effectiveness and safety of pan‐genotypic regimens, glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/daclatasvir (SOF/DCV) and other direct‐acting antivirals (DAA) regimens for the treatment of hepatitis C virus (HCV)‐infected adolescents (12–18 years), older children (6–11 years), and young children (3–5 years). The purpose of this systematic review and meta‐analysis was to inform the World Health Organization (WHO) guidelines.MethodsWe included clinical trials and observational studies published up to August 11, 2021, that evaluated DAA regimens in HCV‐infected adolescents, older children, and young children. We searched MEDLINE, EMBASE, and CENTRAL databases and key conference abstracts. Sustained virological response 12 weeks after the end of treatment (SVR12), adverse events (AEs), and treatment discontinuation were the outcomes evaluated. Risk of bias was assessed using a modified version of the ROBINS‐I tool. Data were pooled using random‐effects models, and certainty of the evidence was assessed using the GRADE approach.ResultsA total of 49 studies including 1882 adolescents, 436 older children, and 166 young children were considered. The SVR12 was 100% (95% Confidence Interval: 96–100), 96% (90–100), and 96% (83–100) for GLE/PIB in adolescents, older, and young children, respectively; 95% (90–99), 93% (86–98), and 83% (70–93), for SOF/VEL, respectively; and 100% (97–100) and 100% (94–100) for SOF/DCV in adolescent and older children, respectively. There was a clear trend towards a higher rate of any reported AE from adolescents (50%), older children (53%), to young children (72%). Serious AEs and treatment discontinuations were uncommon in adolescents and older children (<1%) but slightly higher in young children (3%).ConclusionsAll three pan‐genotypic DAA regimens were highly effective and well‐tolerated and are now recommended by the WHO for use in adults, adolescents, and children down to 3 years, which will simplify procurement and supply chain management. The evidence was based largely on single‐arm non‐randomized controlled studies. Moreover, there were also missing data regarding key variables such as route of HCV acquisition, presence or absence of cirrhosis, or HIV co‐infection that precluded evaluation of the impact of these factors on outcomes.PROSPERO RecordCRD42020146752.

show abstract

Outcomes of daclatasvir + sofosbuvir + riba in HEP C G3 patients who relapsed with SOF + RIBA combination therapy

Cited by 2 publications

References 0 publications

Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan

Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan

Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta‐analysis

Contact Info

Product

Resources

About